Higher pain scores, similar opioid doses and side effects associated with antipyretic analgesics in specialised tertiary pain care
- Jörn LötschAffiliated withpharmazentrum frankfurt/ZAFES, Institute of Clinical Pharmacology, Goethe-University Email author
- , Rainer FreynhagenAffiliated withDepartment of Anaesthesiology, Universitätsklinikum DüsseldorfDepartment of Anaesthesiology, Critical Care Medicine, Pain Therapy and Palliative Care
- , Nils von HentigAffiliated withpharmazentrum frankfurt/ZAFES, Institute of Clinical Pharmacology, Goethe-University
- , Norbert GriessingerAffiliated withDepartment of Anaesthesiology, Universitätsklinikum Erlangen
- , Michael ZimmermannAffiliated withDepartment of Anaesthesia, Intensive Care and Pain Therapy/ZAFES, Goethe-University Hospital
- , Reinhard SittlAffiliated withDepartment of Anaesthesiology, Universitätsklinikum Erlangen
- , Gerd GeisslingerAffiliated withpharmazentrum frankfurt/ZAFES, Institute of Clinical Pharmacology, Goethe-University
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
To evaluate whether non-opioid antipyretic analgesics are associated with lower pain scores, opioid doses and side effects in pain patients in tertiary care.
In a cross-sectional observational study, data from 519 Caucasians (197 men, 322 women; mean age 55.6 ± 15 years) who had undertaken pain therapy for various causes for 77.5 ± 90.8 months, obtained in three separate study centres, was analysed for actual 24-h pain scores, daily opioid doses and the occurrence of side effects.
Of the 519 patients, 352 received opioids and 260 antipyretic analgesics, from whom 154 received both classes and 304 only either class. The administration of non-opioid antipyretic analgesics was associated with higher average pain scores (4.6 ± 2.5 vs 3.9 ± 2.6; P = 0.01), tendentially higher average oral morphine equivalent doses (121.8 ± 162.2 vs 146.7 ± 242.4 mg/d; P = 0.25) and a similar incidence of side effects (P = 0.21). These results were correspondingly seen when analysing the three study centres separately as independent cohorts.
With the caution advised for cross-sectional data, the results dispute a clinical benefit of non-opioid antipyretic analgesics for most chronic pain patients in tertiary care and draw attention towards prospectively re-evaluating the utility of non-opioid antipyretic analgesics in tertiary pain care in a randomised placebo controlled trial.
KeywordsEicosanoids and NSAIDs Pain
- Higher pain scores, similar opioid doses and side effects associated with antipyretic analgesics in specialised tertiary pain care
Volume 59, Issue 11 , pp 989-995
- Cover Date
- Print ISSN
- Online ISSN
- SP Birkhäuser Verlag Basel
- Additional Links
- Eicosanoids and NSAIDs
- Industry Sectors
- Author Affiliations
- 1. pharmazentrum frankfurt/ZAFES, Institute of Clinical Pharmacology, Goethe-University, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
- 2. Department of Anaesthesiology, Universitätsklinikum Düsseldorf, Moorenstraße 5, 40225, Düsseldorf, Germany
- 3. Department of Anaesthesiology, Critical Care Medicine, Pain Therapy and Palliative Care, Benedictus-Krankenhaus Tutzing, Bahnhofstraße 5, 82327, Tutzing, Germany
- 4. Department of Anaesthesiology, Universitätsklinikum Erlangen, Krankenhausstraße 12, 91054, Erlangen, Germany
- 5. Department of Anaesthesia, Intensive Care and Pain Therapy/ZAFES, Goethe-University Hospital, Theodor Stern Kai 7, 60590, Frankfurt, Germany